Markets:

Overview

News

Currencies

International

Treasuries

CytomX Therapeutics, Inc. - Common Stock (NQ:CTMX)

4.420 +0.200 (+4.74%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CytomX Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls ↗

March 17, 2026

Analysts turned bullish, citing strong data and the drug's potential to expand into earlier treatment settings.

Via Stocktwits

Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data ↗

March 16, 2026

Today, March 16, 2026, investors weigh striking early colorectal cancer results against weak quarterly numbers and a finite cash runway.

Via The Motley Fool

Topics Stocks

Monday's session: most active stocks ↗

March 16, 2026

Via Chartmill

These stocks are moving in today's session ↗

March 16, 2026

Via Chartmill

CytomX Therapeutics Inc (NASDAQ:CTMX) Soars 56% on Positive Clinical Data Despite Earnings Miss ↗

March 16, 2026

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Gapping stocks in Monday's session ↗

March 16, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

March 16, 2026

Via Chartmill

Why CTMX Stock Is Soaring 54% Pre-Market Today? ↗

March 16, 2026

CytomX Therapeutics reported promising Phase 1 expansion results for Varseta-M in late-line metastatic colorectal cancer.

Via Stocktwits

Which stocks are experiencing notable movement on Friday? ↗

January 16, 2026

Via Chartmill

A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗

January 15, 2026

Via Chartmill

CytomX Therapeutics Inc (NASDAQ:CTMX) Reports Q3 2025 Earnings Miss, Stock Falls ↗

November 06, 2025

CytomX Therapeutics Q3 2025 earnings miss analyst estimates for revenue and EPS, triggering a negative market reaction.

Via Chartmill

Topics Earnings

CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

October 21, 2025

Via Benzinga

Why CytomX Therapeutics Stock Was Skyrocketing This Week ↗

September 26, 2025

One pundit believes the company might have a winning cancer drug in its pipeline.

Via The Motley Fool

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

September 25, 2025

Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their outstanding shares is at $5.6 million.

Via Benzinga

What's going on in today's after hours session ↗

September 25, 2025

After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.

Via Chartmill

Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket ↗

August 26, 2025

Via Benzinga

Intuit, Workday And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

August 22, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

August 12, 2025

Via Benzinga

CytomX (CTMX) Q2 Revenue Drops 26% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

CytomX Therapeutics Inc (NASDAQ:CTMX) Reports Q2 2025 Revenue Beat and Break-Even EPS ↗

August 07, 2025

CytomX Therapeutics (CTMX) Q2 2025 revenue beat estimates at $18.66M, with break-even EPS. Shares rose slightly as clinical progress, including CX-2051 data, boosts optimism.

Via Chartmill

This Lexeo Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday ↗

July 31, 2025

Via Benzinga

Deep Dive Into CytomX Therapeutics Stock: Analyst Perspectives (4 Ratings) ↗

July 31, 2025

Via Benzinga

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

July 09, 2025

Via Investor Brand Network

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

July 09, 2025

EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - A Strong Contender in High-Growth Biotech ↗

July 08, 2025

CYTOMX THERAPEUTICS (CTMX) meets Minervini’s trend criteria with strong technicals and high-growth fundamentals, making it a candidate for momentum investors.

Via Chartmill

Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday ↗

May 28, 2025

Via Benzinga

CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

May 20, 2025

Via Benzinga

This CytomX Therapeutics Analyst Turns Bullish; Here Are Top 4 Upgrades For Thursday ↗

May 15, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.